First-line Therapy for metastatic hormone-sensitive Prostate Cancer (mHSPC) Randomized, double-blind Phase III Study of Pembrolizumab (MK-3475) plus Enzalutamide plus ADT compared with Placebo Plus Enzalutamide Plus ADT in Participants with metastatic hormone-sensitive Prostate Cancer (mHSPC) (KEYNOTE-991) - AP 108/19 of the AUO

被引：0
|
作者：
Rexer, H. [1 ]
Retz, M. [2 ]
Hammerer, P. [3 ]
机构：
[1] AUO Geschaftsstelle, Schwarz, Germany
[2] Tech Univ Munich, Urol Klin & Poliklin, Klinikum rdl, Munich, Germany
[3] Deutsch Krebsgesellschaft eV, Organgrp Arbeitsgemeinschaft Urol, Berlin, Germany
来源：
UROLOGE | 2021年 / 60卷 / 07期
关键词：
D O I：
10.1007/s00120-021-01570-0
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：987 / 988
页数：2
相关论文
共 50 条
  • [1] KEYNOTE-991: PHASE 3 STUDY OF PEMBROLIZUMAB PLUS ENZALUTAMIDE AND ANDROGEN DEPRIVATION THERAPY (ADT) FOR PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
    Gratzke, Christian
    Gratzke, Christian
    Gratzke, Christian
    Niu, Cuizhen
    Poehlein, Christian
    Burgents, Joseph
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A211 - A211
  • [2] Pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Randomized double-blind phase III KEYNOTE-991 study
    Gratzke, C. J.
    Ozguroglu, M.
    Peer, A.
    Sendur, M. A. N.
    Retz, M.
    Goh, J. C. H.
    Loidl, W. C.
    Jayram, G.
    Byun, S-S.
    Kwak, C.
    Kwiatkowski, M.
    Kopp, R. Manneh
    Limon, J. C. Vazquez
    Penagos, J. F. Escobar
    De Giorgi, U. F. F.
    Trindade, K. M. D.
    Niu, C.
    Liu, Y.
    Poehlein, C. H.
    Rodriguez, J. M. Piulats
    ANNALS OF ONCOLOGY, 2023, 34 : S957 - S958
  • [3] Pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): The phase III KEYNOTE-991 study.
    Gratzke, Christian
    Niu Cuizhen
    Poehlein, Christian Heinrich
    Burgents, Joseph E.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [4] KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer
    Gratzke, Christian
    Kwiatkowski, Mariusz
    Giorgi, Ugo De
    Martins da Trindade, Karine
    De Santis, Maria
    Armstrong, Andrew J.
    Niu, Cuizhen
    Liu, Yingjie
    Poehlein, Christian Heinrich
    FUTURE ONCOLOGY, 2022, 18 (37) : 4079 - 4087
  • [5] Phase III study of pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): KEYNOTE-991.
    Gratzke, Christian
    Burgents, Joseph E.
    Niu, Cuizhen
    Poehlein, Christian Heinrich
    Drak, Charles G.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Efficacy and Safety of Enzalutamide Plus ADT Versus Placebo Plus ADT in Metastatic Hormone-Sensitive Prostate Cancer: The Arches Trial
    Stenzl, A.
    Azad, A.
    Krivoshik, A.
    Baron, B.
    Hirmand, M.
    Armstrong, A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 73 - 73
  • [7] Randomized trial of androgen deprivation therapy (ADT) plus enzalutamide (Arm A) versus ADT plus bicalutamide (Arm B) in metastatic hormone sensitive prostate cancer (mHSPC)
    Vaishampayan, U. N.
    Heilbrun, L.
    Monk, P.
    Sonpavde, G.
    Tejwani, S.
    Heath, E. I.
    Fontana, J.
    Chinni, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [8] AUO First-line Therapy for metastatic hormone-sensitive Prostate Cancer (mHSPC)
    Rexer, H.
    Feyerabend, S.
    Graefen, M.
    UROLOGIE, 2023, 62 (04): : 441 - 442
  • [9] ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC).
    Armstrong, Andrew J.
    Szmulewitz, Russell Zelig
    Petrylak, Daniel Peter
    Holzbeierlein, Jeffrey M.
    Villers, Arnauld
    Azad, Arun
    Alcaraz, Antonio
    Alekseev, Boris Yakovlevich
    Iguchi, Taro
    Shore, Neal D.
    Rosbrook, Brad
    Baron, Benoit
    Chen, Lucy F.
    Stenzl, Arnulf
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) by pattern of metastatic spread: ARCHES post hoc analyses.
    Shore, Neal D.
    Armstrong, Andrew J.
    Szmulewitz, Russell Zelig
    Petrylak, Daniel Peter
    Holzbeierlein, Jeffrey
    Villers, Arnauld
    Azad, Arun
    Alcaraz, Antonio
    Alekseev, Boris
    Iguchi, Taro
    Gomez-Veiga, Francisco
    Rosbrook, Brad
    Lee, Ho-Jin
    Haas, Gabriel P.
    Stenzl, Arnulf
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345